The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR + PR: 13, 29.3%); (CR + PR + MR: 22, 50%); (CR + PR + MR + SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.